Drug intelligence / Profile preview

HRG2005

Development stage: Discontinued
Lead developer: Hengrui Therapeutics
Administration: Inhalation, Oral

Overview

HRG2005 is an investigational drug developed by Jiangsu Hengrui Pharmaceuticals for the treatment of chronic obstructive pulmonary disease (COPD). It is administered via inhalation and oral routes. The precise mechanism of action for HRG2005 has not been defined or disclosed publicly. As of early 2024, it is in Phase 2 clinical trials for COPD in China, with previous Phase 1 studies completed to assess its pharmacokinetics, safety, and tolerability in healthy subjects[1][2][3][6]. No brand names or additional indications have been reported.

Beyond the preview

Go deeper on HRG2005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRG2005.